Seeing more than ever before

A highly sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.

Lymphoma assay extensively validated in hundreds of patients with B-cell malignancies
Detect relapse 200+ days earlier By detecting 1 part per million
See what others miss

Latest Updates

Nov 08, 2023

Foresight Diagnostics Announces Six Presentations Highlighting the Utility of PhasED-Seq™ for Early and Accurate MRD Detection at the 65th American Society of Hematology Annual Meeting

Aug 17, 2023

Foresight Diagnostics Strengthens Leadership Team with Addition of Chief Business Officer John Truesdell

Jun 13, 2023

Foresight Diagnostics Announces Study Demonstrating Prognostic Utility of PhasED-SeqTM for MRD Assessment after Frontline DLBCL Treatment at the 17th International Conference on Malignant Lymphoma